Genetic mutations and immune microenvironment: unveiling the connection to AML prognosis

Hematology. 2024 Dec;29(1):2346965. doi: 10.1080/16078454.2024.2346965. Epub 2024 Apr 30.

Abstract

Background: This study aims to investigate the correlation between NK and NKT cell proportion disparities and prognosis in patients with acute myeloid leukemia (AML).

Methods: Forty-four cases of acute myeloid leukemia patients were selected, and flow cytometry was utilized to evaluate the expression of bone marrow NK and NKT cells. Next-generation sequencing technology was employed to detect genetic mutations in these 44 AML patients, and the rates of first induction remission and overall survival were recorded. Comparisons were made to analyze the respective differences in NK and NKT cell proportions among AML patients with various genetic mutations and risk stratifications.

Results: The FLT-3-ITD+ group exhibited a significant increase in the proportion of NK cells compared to the normal control group and FLT3-ITD+/NPM1+ group, whereas the proportion of NKT cells was significantly decreased. Additionally, the CEBPA+ group showed an increased proportion of NKT cells compared to the TP53+ group and ASXL1+ group. The high-risk group had a higher proportion of NK cells than the intermediate-risk group, while the proportion of NKT cells was lower in the high-risk group compared to the intermediate-risk group.Patients achieving first induction remission displayed a higher proportion of NKT cells at initial diagnosis compared to those who did not achieve remission. The distribution of NK cells show significant differences among AML patients in different survival periods.

Conclusion: This results implies that distinct genetic mutations may play a role not only in tumor initiation but also in shaping the tumor microenvironment, consequently impacting prognosis.

Keywords: Acute myeloid leukemia; NK cells; NKT cells; Next-generation sequencing; first induction remission rate.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Female
  • Humans
  • Killer Cells, Natural* / immunology
  • Killer Cells, Natural* / metabolism
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / immunology
  • Leukemia, Myeloid, Acute* / mortality
  • Male
  • Middle Aged
  • Mutation*
  • Natural Killer T-Cells* / immunology
  • Nucleophosmin*
  • Prognosis
  • Tumor Microenvironment* / immunology
  • Young Adult

Substances

  • Nucleophosmin
  • NPM1 protein, human